Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 688

Sort by

Sort Order Select

Journal Articles

Venetoclax and dexamethasone synergize with inotuzumab ozogamicin–induced DNA damage signaling in B-lineage ALL

Hanna Kirchhoff, Uemran Karsli, Caroline Schoenherr, Karin Battmer, Sergej Erschow, Steven R. Talbot, Doris Steinemann, Michael Heuser, Olaf Heidenreich, Denise Hilfiker-Kleiner, Arnold Ganser, Matthias Eder, Michaela Scherr

Blood (2021) 137 (19): 2657–2661.

https://doi.org/10.1182/blood.2020008544

Published: 2021

Includes: Supplemental data

Journal Articles

Therapeutic inhibition of HIF-2α reverses polycythemia and pulmonary hypertension in murine models of human diseases

Manik C. Ghosh, De-Liang Zhang, Wade H. Ollivierre, Audrey Noguchi, Danielle A. Springer, W. Marston Linehan, Tracey A. Rouault

Blood (2021) 137 (18): 2509–2519.

https://doi.org/10.1182/blood.2020009138

Published: 2021

Includes: Supplemental data

Journal Articles

How I treat cold agglutinin disease

Sigbjørn Berentsen

Blood (2021) 137 (10): 1295–1303.

https://doi.org/10.1182/blood.2019003809

Published: 2021

Journal Articles

Simultaneous Kinase Inhibition with Ibrutinib and BCL2 Inhibition with Venetoclax As a Therapeutic Strategy for Acute Lymphoblastic Leukemia

Christopher A. Eide, Stephen E Kurtz, PhD, Andy Kaempf, MS, Nicola Long, Jessica Leonard, MD, Bill H. Chang, MD PhD, Motomi Mori, PhD, Brian J. Druker, Jeffrey W. Tyner

Blood (2019) 134 (Supplement_1): 3950.

https://doi.org/10.1182/blood-2019-131288

Published: 2019

Journal Articles

Identification of Novel Variants Associated with Fetal Hemoglobin Levels in Healthy Donors (the INTERVAL study)

Emily Kawabata, Samuel Lessard, PhD, Dirk Paul, Paola G Bronson, Robert Peters, Sriram Krishnamoorthy, PhD, William Astle, Adam Butterworth

Blood (2019) 134 (Supplement_1): 2243.

https://doi.org/10.1182/blood-2019-123977

Published: 2019

Journal Articles

2'-O-Methoxyethyl Splice-Switching Oligos to Reverse Splicing from IVS2-745 β-Thalassemia Patient Cells: A Foundation for Potential Therapies

Blood (2019) 134 (Supplement_1): 2244.

https://doi.org/10.1182/blood-2019-127017

Published: 2019

Journal Articles

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Initial Immunosuppression Regimen

Katerina Pavenski, MD, Paul Knoebl, MD, Marie Scully, Johanna A. Kremer Hovinga, MD Prof, Paul Coppo, MD PhD, Flora Peyvandi, MD PhD, Spero Cataland, MD, Ara Metjian, MD, Javier De La Rubia, Hilde De Winter, MD, Rui de Passos Sousa, Filip Callewaert

Blood (2019) 134 (Supplement_1): 2365.

https://doi.org/10.1182/blood-2019-123126

Published: 2019

Journal Articles

A Phase 3 Study of Eltrombopag Vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children

Kristin A. Shimano, MD, Rachael F. Grace, MD, Carolyn M. Bennett, MDMSc, Robert J Klaassen, MD FRCPC, Cindy Neunert, MD, Ellis J. Neufeld, MD, Clement Ma, PhD, Wendy B. London, PhD, Jenny M. Despotovic, DO, MS

Blood (2019) 134 (Supplement_1): 2369.

https://doi.org/10.1182/blood-2019-125487

Published: 2019

Journal Articles

Case Series: Outcome and Cost Analysis of Rituximab Versus Non-Targeted Immunosuppression As First Line Inhibitor Eradication in Acquired Hemophilia a

Ellen Cusano, Adrienne Lee, MD, Julia Hews-Girard, RN BScN MN

Blood (2019) 134 (Supplement_1): 2399.

https://doi.org/10.1182/blood-2019-129665

Published: 2019

Journal Articles

REVEAL: Characteristics of Patients with Polycythemia Vera Who Were Diagnosed within 6 Months of Enrollment

Aaron T. Gerds, MD MS, Ivy Altomare, MD, Philomena Colucci, DO, MS, Dilan Paranagama, PhD, John M Burke, MD

Blood (2019) 134 (Supplement_1): 5370.

https://doi.org/10.1182/blood-2019-121386

Published: 2019

Journal Articles

Review of 20 Years Outcome of Multiple Myeloma Novel Agent Era at Samsung Medical Center, a Korean Cancer Center

Sang Eun Yoon, MD, Seok Jin Kim, MD PhD, Kihyun Kim, MD PhD

Blood (2019) 134 (Supplement_1): 5585.

https://doi.org/10.1182/blood-2019-127872

Published: 2019

Journal Articles

Panobinostat (LBH589) in Combination with the β-Catenin Inhibitor Tegavivint (BC2059) Exerts Significant Anti-Myeloma Activity Both in Vitro and In Vivo

Ioanna Savvidou, MD, Tiffany Khong, BSc, PhD, Sophie Whish, Tara Sepehrizadeh, Sridurga Mithraprabhu, PhD MSc, Michael DeVeer, BSc, PhD, Andrew Spencer, DM

Blood (2019) 134 (Supplement_1): 5540.

https://doi.org/10.1182/blood-2019-126468

Published: 2019

Journal Articles

Nascent Transcript and Single Cell Rnaseq Analysis Defines the Mechanism of Action of the LSD1 Inhibitor INCB059872 in Myeloid Leukemia

Gretchen Johnston, Haley E. Ramsey, PhDMSc, Kristy Stengel, PhD, Shilpa Sampathi, PhD, Pankaj Acharya, PhD, Maria Arrate, MSc, Matthew C. Stubbs, PhD, Timothy Burn, PhD, Scott Hiebert, PhD, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 2509.

https://doi.org/10.1182/blood-2019-130458

Published: 2019

Journal Articles

Endogenous Retinoid X Receptor Ligands Act As Tumor Suppressors in MLL-AF9 Mouse Leukemia

Orsola Di Martino, PhD, Margaret Y Ferris, MD PhD, Hadwiger Gayla, Haixia Niu, PhD, John S. Welch, MD PhD

Blood (2019) 134 (Supplement_1): 2677.

https://doi.org/10.1182/blood-2019-128869

Published: 2019

Journal Articles

CCS1477: A Novel Small Molecule Inhibitor of p300/CBP Bromodomain for the Treatment of Acute Myeloid Leukaemia and Multiple Myeloma

Nigel Brooks, PhD, Meera Raja, PhD, Barbara W Young, PhD, Gary J Spencer, PhD, Tim CP Somervaille, MD PhD, Neil A Pegg, PhD

Blood (2019) 134 (Supplement_1): 2560.

https://doi.org/10.1182/blood-2019-124707

Published: 2019

Journal Articles

Evolution of Clinically Relevant Subclones during Chemotherapy Treatment of ALL As Determined By Single-Cell DNA and RNA Sequencing

Llucia Albertí Servera, PhD, Sofie Demeyer, PhD, Inge Govaerts, MD PhD, Olga Gielen, Heidi Segers, MD PhD, Anne Uyttebroeck, MD, Nancy Boeckx, Johan A. Maertens, MD PhD, Kim De Keersmaecker, PhD, Jan Cools, PhD

Blood (2019) 134 (Supplement_1): 2749.

https://doi.org/10.1182/blood-2019-123046

Published: 2019

Journal Articles

Combination Treatment with Imetelstat, a Telomerase Inhibitor, and Ruxolitinib Depletes Myelofibrosis Hematopoietic Stem Cells and Progenitor Cells

Cing Siang Hu, Fei Huang, Ronald Hoffman, MD, Xiaoli Wang, MD PhD

Blood (2019) 134 (Supplement_1): 2963.

https://doi.org/10.1182/blood-2019-126189

Published: 2019

Journal Articles

Therapeutic Stratification of PTEN-MYC Axis Appears to be Promising for Molecular Targeted Therapies in Refractory and Relapsed T-Cell Acute Lymphoblastic Leukemia

Heinz Ahlert, MSc, BSc, Sanil Bhatia, PhD, Marc Remke, MD, Melf Sönnichsen, M.Sc., Niklas Dienstbier, M.Sc., Ute Fischer, PhD, Julia Hauer, MD, Arndt Borkhardt, MD

Blood (2019) 134 (Supplement_1): 3883.

https://doi.org/10.1182/blood-2019-128136

Published: 2019

Journal Articles

Population-Based, Cause-Specific Risk of Non-Lymphoma Deaths Among 20,491 Adults with Classical Hodgkin Lymphoma (cHL) Treated with Initial Chemotherapy in the United States, 2000-2015

Graca M. Dores, MD, Rochelle E. Curtis, MA, Nicole H. Dalal, BA, Martha S. Linet, MD MPH, Lindsay M. Morton, PhD

Blood (2019) 134 (Supplement_1): 4034.

https://doi.org/10.1182/blood-2019-124831

Published: 2019

Journal Articles

Harnessing the Epichaperome As a Therapeutic Approach in Multiple Myeloma

Eloisi Caldas Lopes, PhD, Tai Wang, PhD, David S Jayabalan, MSc, Tony Taldone, PhD, Jorge Monge, MD, Jorge Contreras, MD, Yip Winnie, Vicenta Trujillo, PhD, Panchal Palak, Nicholas Lombardi, Sharma Sahil, PhD, Digwal Chander, PhD, Morton Coleman, MD, Gabriela Chiosis, PhD, Ruben Niesvizky, MD, Monica L. Guzman, PhD

Blood (2019) 134 (Supplement_1): 4399.

https://doi.org/10.1182/blood-2019-125267

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Venetoclax and dexamethasone synergize with inotuzumab ozogamicin–induced DNA damage signaling in B-lineage ALL

Therapeutic inhibition of HIF-2α reverses polycythemia and pulmonary hypertension in murine models of human diseases

How I treat cold agglutinin disease

Simultaneous Kinase Inhibition with Ibrutinib and BCL2 Inhibition with Venetoclax As a Therapeutic Strategy for Acute Lymphoblastic Leukemia

Identification of Novel Variants Associated with Fetal Hemoglobin Levels in Healthy Donors (the INTERVAL study)

2'-O-Methoxyethyl Splice-Switching Oligos to Reverse Splicing from IVS2-745 β-Thalassemia Patient Cells: A Foundation for Potential Therapies

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Initial Immunosuppression Regimen

A Phase 3 Study of Eltrombopag Vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children

Case Series: Outcome and Cost Analysis of Rituximab Versus Non-Targeted Immunosuppression As First Line Inhibitor Eradication in Acquired Hemophilia a

REVEAL: Characteristics of Patients with Polycythemia Vera Who Were Diagnosed within 6 Months of Enrollment

Review of 20 Years Outcome of Multiple Myeloma Novel Agent Era at Samsung Medical Center, a Korean Cancer Center

Panobinostat (LBH589) in Combination with the β-Catenin Inhibitor Tegavivint (BC2059) Exerts Significant Anti-Myeloma Activity Both in Vitro and In Vivo

Nascent Transcript and Single Cell Rnaseq Analysis Defines the Mechanism of Action of the LSD1 Inhibitor INCB059872 in Myeloid Leukemia

Endogenous Retinoid X Receptor Ligands Act As Tumor Suppressors in MLL-AF9 Mouse Leukemia

CCS1477: A Novel Small Molecule Inhibitor of p300/CBP Bromodomain for the Treatment of Acute Myeloid Leukaemia and Multiple Myeloma

Evolution of Clinically Relevant Subclones during Chemotherapy Treatment of ALL As Determined By Single-Cell DNA and RNA Sequencing

Combination Treatment with Imetelstat, a Telomerase Inhibitor, and Ruxolitinib Depletes Myelofibrosis Hematopoietic Stem Cells and Progenitor Cells

Therapeutic Stratification of PTEN-MYC Axis Appears to be Promising for Molecular Targeted Therapies in Refractory and Relapsed T-Cell Acute Lymphoblastic Leukemia

Population-Based, Cause-Specific Risk of Non-Lymphoma Deaths Among 20,491 Adults with Classical Hodgkin Lymphoma (cHL) Treated with Initial Chemotherapy in the United States, 2000-2015

Harnessing the Epichaperome As a Therapeutic Approach in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only